Vidac Pharma Holding (STU:T9G) Debt-to-Asset : 3.03 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding Debt-to-Asset?

Vidac Pharma Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.33 Mil. Vidac Pharma Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Vidac Pharma Holding's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €0.11 Mil. Vidac Pharma Holding's debt to asset for the quarter that ended in Jun. 2024 was 3.03.

Vidac Pharma Holding Debt-to-Asset Historical Data

The historical data trend for Vidac Pharma Holding's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding Debt-to-Asset Chart

Vidac Pharma Holding Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

8.83

1.20

Vidac Pharma Holding Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial			0.88	8.83	-	1.20	3.03

Competitive Comparison of Vidac Pharma Holding's Debt-to-Asset

For the Biotechnology subindustry, Vidac Pharma Holding's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Vidac Pharma Holding Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vidac Pharma Holding's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.165	+	0)	/	0.138
	=	1.20

Vidac Pharma Holding's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.33	+	0)	/	0.109
	=	3.03

Vidac Pharma Holding (STU:T9G) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Vidac Pharma Holding Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Wenlock Road, 20-22, London, GBR, N1 7GU

Website

https://www.vidacpharma.com

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines